Papers/PMID:41184790
Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
BMC psychiatry2025The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
sulforaphane — decreases triglycerides
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol.”
Quoted verbatim from Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- Patients with schizophrenia in pooled randomized controlled trials of sulforaphane versus control
Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.2025PMID:41184790Permalink